



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Announcement Type

New announcement

Date of this announcement

Friday May 16, 2025

The +securities to be quoted are:

+Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
TLX	ORDINARY FULLY PAID	139,383	12/05/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

16/5/2025



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

+Securities issued, transferred or re-classified as a result of options being exercised or other +convertible securities being converted

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Existing +securities converting into additional +securities in an existing class

FROM (Existing Class)

ASX +security code and description

TLXAO : SHARE APPRECIATION RIGHTS

TO (Existing Class)

ASX +security code and description

TLX : ORDINARY FULLY PAID

Please state the number of options that were exercised or other +convertible securities that were converted

127,818

The first date the options were exercised or other +convertible securities were converted

2/5/2025

The last date the options were exercised or other +convertible securities were converted

12/5/2025

Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?

No

The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:

An issue of new +securities

The underlying +securities being received by the holder are:

Intended to be, but are not yet, quoted by ASX

Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?

Yes

Are any of the options being exercised or other +convertible securities being converted held by +key management personnel (KMP) or an +associate?

No

Issue date

12/5/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes



Issue details

Number of +securities to be quoted

105,671

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Shares issued from exercise of vested 2022 PSARs under Telix Equity Incentive Plan valued using a \$4.95 notional exercise price in accordance with the independent Black Scholes methodology

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

4.950000

Any other information the entity wishes to provide about the +securities to be quoted

Refer <https://ir.telixpharma.com/reports> for AGM documentation and also Telix 2024 Remuneration report within the 2024 Annual Report

Existing +securities converting into additional +securities in an existing class**FROM (Existing Class)****ASX +security code and description**

TLXAO : SHARE APPRECIATION RIGHTS

TO (Existing Class)**ASX +security code and description**

TLX : ORDINARY FULLY PAID

Please state the number of options that were exercised or other +convertible securities that were converted

43,323

The first date the options were exercised or other +convertible securities were converted

5/5/2025

The last date the options were exercised or other +convertible securities were converted

12/5/2025

Is this all of the options or other +convertible securities on issue of that type (ie have all of those options now been exercised or have all of those convertible securities now been converted)?

No

The right of the holder of the options or other +convertible securities to receive the +underlying securities is being satisfied by:

An issue of new +securities

The underlying +securities being received by the holder are:

Intended to be, but are not yet, quoted by ASX

Were the options being exercised or other +convertible securities being converted issued under an +employee incentive scheme?

Yes

Are any of the options being exercised or other +convertible securities being converted held by +key management personnel (KMP) or an +associate?

No

Issue date

12/5/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued



+securities in that class?

Yes

Issue details

Number of +securities to be quoted

33,712

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Shares issued from exercise of vested 2022 PSARs under Telix EIP are valued in accordance with the independent Black Scholes methodology disclosed in the AGM Notice of Meeting held 18 May 2022.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

6.150000

Any other information the entity wishes to provide about the +securities to be quoted

Refer <https://ir.telixpharma.com/reports> for AGM documentation and also Telix 2024 Remuneration report within the 2024 Annual Report



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	338,109,048

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,800,000
TLXAO : SHARE APPRECIATION RIGHTS	14,223,198
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	304,992
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	330,437
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000